| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | B23; NPM |
| Entrez GeneID | 4869 |
| WB Predicted band size | Calculated MW: 33 kDa; Observed MW: 38 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human Nucleophosmin |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于Nucleophosmin(NPM1)抗体的3篇参考文献及其摘要概括：
---
1. **文献名称**：*"Nucleophosmin: from structure and function to disease development"*
**作者**：Colombo E, et al.
**摘要**：该综述系统总结了NPM1的分子结构、生理功能及其在癌症(如白血病、实体瘤)中的异常表达。文中提到针对NPM1的单克隆抗体在临床诊断(如免疫组化检测胞质定位)和机制研究(如蛋白相互作用分析)中的关键作用。
---
2. **文献名称**：*"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype"*
**作者**：Falini B, et al.
**摘要**：研究发现约35%的急性髓系白血病(AML)患者存在NPM1基因突变，导致蛋白异常定位于细胞质。通过特异性抗体(如抗NPM1单克隆抗体)进行免疫组化，可快速鉴别此类突变，成为AML分型的重要标志物。
---
3. **文献名称**：*"NPM1 mutations induce a mutator phenotype in acute myeloid leukemia via aberrant AID activity"*
**作者**：Pasqualucci L, et al.
**摘要**：文章探讨了NPM1突变如何通过干扰DNA修复机制促进白血病发生。研究中利用NPM1抗体进行Western blot和免疫共沉淀实验，证实突变型NPM1与AID蛋白的异常结合，揭示了其致基因组不稳定的机制。
---
4. **文献名称**：*"Antibody-based detection of nucleophosmin mutations in acute myeloid leukemia"*
**作者**：Aljabri M, et al.
**摘要**：该研究开发了一种基于特异性抗体的ELISA检测方法，用于快速筛查AML患者中NPM1的常见突变(如A型突变)。该方法与基因测序结果高度一致，为临床提供了一种低成本、高通量的突变筛查工具。
---
以上文献涵盖了NPM1抗体的基础研究、临床应用及检测技术开发，均为领域内高影响力研究。
Nucleophosmin (NPM), also known as B23 or NPM1. is a multifunctional phosphoprotein primarily localized in the nucleolus. It plays critical roles in ribosome biogenesis, centrosome duplication, cell cycle regulation, and genomic stability. NPM shuttles between the nucleolus, nucleus, and cytoplasm, participating in processes like chromatin remodeling, DNA repair, and apoptosis. Its involvement in diverse cellular pathways makes it a key focus in cancer research, particularly in hematologic malignancies.
NPM antibodies are essential tools for detecting and studying this protein in research and diagnostics. In normal cells, NPM antibodies help visualize nucleolar organization and monitor protein dynamics during stress or cell division. However, their clinical significance is most notable in acute myeloid leukemia (AML), where mutations in the NPM1 gene (exon 12 insertions) result in aberrant cytoplasmic localization of NPM (NPMc+). Antibodies specific to mutant NPM are used diagnostically to identify this AML subtype, which correlates with prognosis and treatment response.
Beyond cancer, NPM antibodies aid in studying viral infections, neurodegenerative diseases, and ribosomopathies. They are employed in techniques like immunohistochemistry, Western blotting, and immunofluorescence. Challenges include distinguishing between NPM isoforms and ensuring specificity due to post-translational modifications. Ongoing research aims to refine antibody-based assays for precision medicine, underscoring NPM's role as both a biomarker and a therapeutic target.
(Word count: 250)
×
